Contribute Try STAT+ Today

Rise and shine, everyone, another challenging day is on the way. We can tell because our short person is up early for another day of online learning, such as it is, and the official mascot is running about in search of tasty things to chew. As for us, we are resorting to our usual habit of brewing cups of stimulation — our choice today is glazed doughnut — and, as always, we invite you to join us. Remember, no prescription is required. Meanwhile, here are some tidbits to help you along. Stay in touch and stay safe.

India plans to ramp up production of pharmaceutical ingredients and become an alternative supplier for global drug makers hit by factory shutdowns in China due to the coronavirus outbreak, Bloomberg News says. The Indian government has aggressively begun implementing a policy to ramp up local output and emerge as an alternate to China. The “China-plus one” strategy involves identifying essential drug ingredients, providing incentives to domestic manufacturers, and reviving ailing state-run drug makers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.